- Home
- GERN vs NVRI Comparison
GERN vs NVRI Comparison
Compare GERN & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- NVRI
- Stock Information
- Founded
- GERN 1990
- NVRI 1853
- Country
- GERN United States
- NVRI United States
- Employees
- GERN N/A
- NVRI N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- NVRI Diversified Commercial Services
- Sector
- GERN Health Care
- NVRI Miscellaneous
- Exchange
- GERN Nasdaq
- NVRI Nasdaq
- Market Cap
- GERN 823.0M
- NVRI 931.5M
- IPO Year
- GERN 1996
- NVRI N/A
- Fundamental
- Price
- GERN $1.38
- NVRI $11.74
- Analyst Decision
- GERN Buy
- NVRI Hold
- Analyst Count
- GERN 7
- NVRI 1
- Target Price
- GERN $3.17
- NVRI $10.00
- AVG Volume (30 Days)
- GERN 6.7M
- NVRI 1.2M
- Earning Date
- GERN 11-06-2025
- NVRI 10-30-2025
- Dividend Yield
- GERN N/A
- NVRI N/A
- EPS Growth
- GERN N/A
- NVRI N/A
- EPS
- GERN N/A
- NVRI N/A
- Revenue
- GERN $164,447,000.00
- NVRI $2,242,873,000.00
- Revenue This Year
- GERN $175.15
- NVRI N/A
- Revenue Next Year
- GERN $56.61
- NVRI $3.72
- P/E Ratio
- GERN N/A
- NVRI N/A
- Revenue Growth
- GERN 11877.20
- NVRI N/A
- 52 Week Low
- GERN $1.09
- NVRI $4.72
- 52 Week High
- GERN $4.50
- NVRI $12.84
- Technical
- Relative Strength Index (RSI)
- GERN 44.59
- NVRI 52.50
- Support Level
- GERN $1.26
- NVRI $11.53
- Resistance Level
- GERN $1.48
- NVRI $12.09
- Average True Range (ATR)
- GERN 0.07
- NVRI 0.42
- MACD
- GERN -0.00
- NVRI -0.18
- Stochastic Oscillator
- GERN 13.64
- NVRI 20.00
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.